Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 15/20 | 0.55 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24984253 | 1.00 | STING1 (0.61) | STING1MEN1MAPTKMT2AABCB1 | |
| SCHEMBL4674783 | 0.95 | MEN1 (0.61) | STING1MEN1MAPTKMT2AABCB1 | |
| SCHEMBL4674780 | 0.95 | MEN1 (0.61) | STING1MEN1MAPTKMT2AABCB1 | |
| SCHEMBL4639560 | 0.95 | MEN1 (0.61) | STING1MEN1MAPTKMT2AABCB1 | |
| SCHEMBL4639566 | 0.95 | MEN1 (0.61) | STING1MEN1MAPTKMT2AABCB1 | |
| SCHEMBL4639562 | 0.95 | MEN1 (0.61) | STING1MEN1MAPTKMT2AABCB1 | |
| SCHEMBL30141243 | 0.95 | STING1 (0.56) | STING1MEN1MAPTKMT2AABCB1 | |
| SCHEMBL24983694 | 0.94 | STING1 (0.68) | STING1MEN1MAPTKMT2AABCB1 | |
| SCHEMBL30141038 | 0.94 | STING1 (0.68) | STING1MEN1MAPTKMT2AABCB1 | |
| SCHEMBL30141024 | 0.93 | STING1 (0.54) | STING1MEN1MAPTKMT2AABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336588-A1 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | AVANTI BIOSCIENCES, INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2023288020-A1 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | AVANTI BIOSCIENCES INC. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336588-A1 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | MPO, GPX4, GPX1 | STING1 803/4885MEN1 4827/4885MAPT 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.